Document Detail

LDP-02 (Millenium).
MedLine Citation:
PMID:  11566006     Owner:  NLM     Status:  MEDLINE    
Millennium (formerly LeukoSite) and Genentech are developing LDP-02, a humanized monoclonal antibody to the alpha4beta7 integrin receptor on leukocytes, for potential use in the treatment of inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis [274580]. LeukoSite intended to develop iv and sc formulations of LDP-02 for acute IBD [315156]. In December 1997, Genentech entered into a collaboration with LeukoSite to develop and commercialize LDP-02 for the treatment of IBD [275395], [279420]. A phase II SBIR grant was awarded to LeukoSite in September 1996. The US $750,000 grant was used to develop LDP-02 and to conduct preclinical tests on the antibody for the treatment of IBD [218689]. In February 1999, Lehman Brothers predicted the drug had a 10% probability of reaching market. Assuming a successful launch, Lehman Brothers analysts estimated peak sales would occur in 2011 with sales at that time of US $250 million [319225].
J K Marshall
Related Documents :
1460626 - Clothing impregnations of dibutylphthalate and permethrin as protectants against a chig...
9180056 - Ethical decision-making in newborn infants.
10897816 - Successful chemotherapeutic treatment of diencephalic syndrome with continued tumor pre...
25028056 - Effect of miscarriage history on maternal-infant bonding during the first year postpart...
20032496 - Neutral and acidic oligosaccharides in preterm infants: a randomized, double-blind, pla...
21981106 - Recurrent spontaneous hypoglycaemia causes loss of neurogenic and neuroglycopaenic sign...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in investigational drugs (London, England : 2000)     Volume:  2     ISSN:  1472-4472     ISO Abbreviation:  Curr Opin Investig Drugs     Publication Date:  2001 Apr 
Date Detail:
Created Date:  2001-09-21     Completed Date:  2001-12-04     Revised Date:  2011-08-01    
Medline Journal Info:
Nlm Unique ID:  100965718     Medline TA:  Curr Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  502-4     Citation Subset:  IM    
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / adverse effects,  metabolism,  therapeutic use*
Clinical Trials as Topic
Colitis, Ulcerative / therapy*
Crohn Disease / therapy*
Integrins / immunology*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Integrins; 0/LDP-02 monoclonal antibody; 0/integrin alpha4beta7

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Inflammatory mediators as therapeutic targets in acute pancreatitis.
Next Document:  ALX-0600 (NPS Allelix Corp).